Small molecule modulators targeting protein kinase CK1 and CK2

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Casein kinase (CK) is a serine/threonine protein kinase involved in critical cellular signaling pathways.
• CK plays a significant role in inflammation, cancer, and nervous system disorders, making it a key therapeutic target.
• Existing CK inhibitors often lack essential properties for in vivo application, such as selectivity and metabolic stability.

Purpose of the Study:

• To review published casein kinase inhibitors.
• To analyze structure-activity relationships (SAR) of these inhibitors.
• To provide insights for future drug discovery targeting CK.

Main Methods:

• Literature review of casein kinase inhibitors.
• Analysis of structure-activity relationships (SAR).
• Summary of eutectic structures and identified hot spots.

Main Results:

• Many ATP-competitive CK inhibitors have been developed, but face challenges in clinical application.
• CX-4945 is the sole CK2 inhibitor currently in Phase II clinical trials.
• Advances in non-competitive inhibitor design and multi-target strategies are emerging.

Conclusions:

• Small molecule inhibitors offer controllable pharmacological and pharmacokinetic properties for drug development.
• Understanding SAR and utilizing strategies like multi-target inhibition are vital for advancing CK-targeted therapies.
• This review serves as a reference for future drug discovery efforts in the field of casein kinase inhibition.